As of September 30, 2026, Adicet Bio, Inc. carries a market capitalization of 66.84M, placing it among publicly traded companies globally. Its enterprise value stands at -22.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 66.84M |
| Enterprise Value | -22.00M |
Adicet Bio, Inc.'s next confirmed earnings release is scheduled for March 17, 2027.
| Earnings Date | 3/17/2027 |
As of September 30, 2026, Adicet Bio, Inc. has 9.36M shares outstanding.
| Shares Outstanding | 9.36M |
These figures are as of September 30, 2026.
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | -0.95 |
| P/OCF Ratio | -0.95 |
As of September 30, 2026, Adicet Bio, Inc. maintains a current ratio of 6.09, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.78, indicating elevated leverage, while an interest coverage ratio of -983.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.09 |
| Quick Ratio | 5.96 |
| Debt / Equity | 11.78 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -983.70 |
Over the twelve months ended September 30, 2026, Adicet Bio, Inc. posted a negative return on equity (ROE) of -85.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -67.55, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 102.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -85.91 |
| Return on Assets (ROA) | -67.55 |
| Employee Count | 102.00 |
Over the twelve months ended September 30, 2026, Adicet Bio, Inc. recorded 144,000.00 in income tax expense. The company reported a pretax loss of -90.85M and -91.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 144,000.00 |
As of the close on November 16, 2026, Adicet Bio, Inc.'s stock has declined approximately 74.05% over the past 52 weeks. The 50-day moving average sits at 5.80, while the 200-day moving average is 7.40.
| 52-Week Price Change | -74.05% |
| 50-Day Moving Average | 5.80 |
| 200-Day Moving Average | 7.40 |
Over the twelve months ended September 30, 2026, Adicet Bio, Inc. generated - - in revenue and converted that into -91.00M in net income, yielding earnings per share of -8.54. EBITDA reached -90.50M, while operating income came in at -95.55M.
| Operating Income | -95.55M |
| Pretax Income | -90.85M |
| Net Income | -91.00M |
| EBITDA | -90.50M |
| EBIT | -95.55M |
| Earnings Per Share (EPS) | -8.54 |
As of September 30, 2026, Adicet Bio, Inc. holds 100.95M in cash and equivalents against 12.10M in total debt, resulting in a net debt position of -27.11M. Total book value stands at 102.70M, with working capital of 86.45M providing operational flexibility.
| Cash & Cash Equivalents | 100.95M |
| Total Debt | 12.10M |
| Net Debt | -27.11M |
| Equity (Book Value) | 102.70M |
| Book Value Per Share | 10.97 |
| Working Capital | 86.45M |
Adicet Bio, Inc. produced -80.14M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -285,000.00 in capital expenditures, free cash flow totaled -80.43M - equivalent to -7.55 per share.
| Operating Cash Flow | -80.14M |
| Capital Expenditures | -285,000.00 |
| Free Cash Flow | -80.43M |
| FCF Per Share | -7.55 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -105.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -112.54, meaning Adicet Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -112.54 |
| FCF Yield | -105.76 |
Adicet Bio, Inc.'s most recent stock split took place on December 30, 2025 with a 16:1 split ratio.
| Last Split Date | 12/30/2025 |
| Split Ratio | 16:1 |
As of September 30, 2026, Adicet Bio, Inc. has an Altman Z-Score of -7.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.44 |